Search reports, ask a question, or jump to a page.
The problem
Intervention: Varicella vaccination with two different schedules: two doses of tetravalent measles-mumps-rubella-varicella vaccine, or one dose of monovalent varicella vaccine combined with measles-mumps-rubella vaccine
Who it was tested with: Children aged 12-22 months in Norway and Sweden (n=5803 across 10 European countries, with data extracted for Norwegian and Swedish populations).
Children or communities are compared with a group that did not receive the intervention, or followed over years. This is the design that best separates what the intervention did from everything else that changed.
"This was an observer-blind, controlled trial conducted in 10 European countries. Children aged 12-22 months (n = 5803) were randomised 3:3:1 and vaccinated between 1 September 2005 and 10 May 2006." This describes a randomised experimental design with comparison groups across a 10-year follow-up period, providing strong evidence for vaccine efficacy and safety.
Randomisation was 3:3:1 rather than 1:1:1, which may affect statistical comparisons. The study was conducted in 2005-2006, so findings may not reflect current vaccine formulations or epidemiology. Limited detail provided on specific adverse events or duration of immunity beyond study period.
Across countries and designs
5 studies · 3 countries
